Profound Medical Corp.
PROF Nasdaq
SEC CIK 1628808
Follow Profound Medical Corp.
Weekly email: filings, results
Revenue, last quarter
$9.8M
+94.3% vs same quarter last year
Net income
−$7.7M
+3.2% vs same quarter last year
EPS, diluted
−$0.21
+19.2% vs same quarter last year
Operating cash flow
−$5M
+47.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Revenue |
|---|---|
| FY25 | $16.1M |
| FY24 | $9.7M |
| FY23 | $5.9M |
| FY22 | - |
- Gross margin
- Operating margin
Show the numbers
| Year | Gross margin | Operating margin |
|---|---|---|
| FY25 | 70.8% | −256.3% |
| FY24 | 72.2% | −339.4% |
| FY23 | 73.1% | −485.7% |
| FY22 | - | - |